U.S. markets open in 8 hours 3 minutes

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
27.38-0.64 (-2.28%)
At close: 4:00PM EDT

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500
http://www.supernus.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees563

Key Executives

NameTitlePayExercisedYear Born
Mr. Jack A. KhattarFounder, Pres, CEO, Sec. & Director1.68MN/A1961
Mr. James Patrick KellyExec. VP & CFO519.48kN/A1966
Dr. Padmanabh P. BhattChief Scientific Officer & Sr. VP of Intellectual Property582.2kN/A1957
Ms. Tami T. MartinSr. VP of Regulatory Affairs495.2kN/A1955
Mr. Kevin T. AndersonCompliance OfficerN/AN/A1962
Dr. Todd Horich M.B.A., Ph.D.Sr. VP of Marketing & Market AccessN/AN/AN/A
Mr. Taylor RaifordSr. VP of SalesN/AN/AN/A
Dr. Bryan A. Roecklein Ph.D.Sr. VP of Corp. Devel.N/AN/AN/A
Mr. Frank MottolaSr. VP of Quality, GMP Operations & Information TechnologyN/AN/A1972
Dr. Jonathan RubinSr. VP of R&D and Chief Medical OfficerN/AN/A1961
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.

Corporate Governance

Supernus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.